A new center has been established to support customers and accelerate the development of personalized treatments in the cell and gene therapy (CGT) field.

The CGT Vision Centre will offer access to advanced technologies, regulatory expertise, and comprehensive workflow solutions for its clients.

Soo Jin Seok of Thermo Fisher highlighted the necessity for specialized support in CGT innovations, from discovery through to commercialization.

The CGT market was valued at approximately $0.489 billion in 2023, having experienced a compound annual growth rate (CAGR) of 21.2% over the past five years.

Market forecasts indicate that South Korea's cell and gene therapy market is set to grow at a CAGR of 16.9%, potentially reaching $1.067 billion by 2027.

In 2022, the market reached a valuation of $0.403 billion, reflecting significant growth in the sector.